New treatments for liver cancer by targeting a specific protein
Therapeutic targeting of FGF19-driven cancers with FGF21 variants
This research explores new ways to treat a common type of liver cancer by focusing on a protein called FGF19 that helps cancer grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11103305 on NIH RePORTER |
What this research studies
Liver cancer, especially hepatocellular carcinoma (HCC), is a serious and rapidly increasing health concern with limited treatment options. Many patients with advanced HCC face a low five-year survival rate, highlighting the urgent need for better therapies. This project focuses on a specific protein, FGF19, which has been found to drive cancer growth in some HCC patients. We are developing modified versions of another protein, FGF21, that can block the harmful effects of FGF19 and potentially stop cancer cells from multiplying. Our goal is to create a new treatment approach for patients whose liver cancer is fueled by FGF19.
Who could benefit from this research
Good fit: This foundational research is for future patients diagnosed with hepatocellular carcinoma (HCC) where the FGF19 protein is driving their cancer growth.
Not a fit: Patients whose liver cancer is not driven by the FGF19 protein may not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment option for patients with FGF19-driven liver cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have helped us understand how FGF19 and FGF21 interact, providing a strong foundation for developing these new therapeutic variants.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Lee, Sangwon — Yale University
- Study coordinator: Lee, Sangwon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.